These results demonstrated that the administration of an anti-IL-10 antibody was able to trigger the antitumoral effect of mifamurtide in the aggressive OS tumor cells, whereas a single treatment with mifamurtide had no efficacy. The gene discussed is IL10; the disease is neoplasm.